Results 1 to 10 of about 16,733 (229)

The Revival of Aztreonam in Combination with Avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases [PDF]

Antibiotics, 2021
Infections caused by metallo-β-lactamase (MBL)-producing Enterobacterales and Pseudomonas are increasingly reported worldwide and are usually associated with high mortality rates (>30%).
Carola Mauri, Alberto Enrico Maraolo, Stefano Di Bella, Francesco Luzzaro, Luigi Principe   +4 more
doaj   +5 more sources

Population pharmacokinetic/pharmacodynamic modeling to optimize aztreonam-avibactam dose regimens for adult patients. [PDF]

Antimicrob Agents Chemother
Aztreonam-avibactam, a fixed-ratio (3:1) β-lactam/β-lactamase inhibitor combination, was approved in Europe in 2024 for adults with complicated intra-abdominal infection (cIAI), complicated urinary tract infection, hospital-acquired/ventilator-associated
Xie R, Rogers H, Chow JW, Soto E, Raber SR.   +4 more
europepmc   +4 more sources

Aztreonam-avibactam: The dynamic duo against multidrug-resistant gram-negative pathogens. [PDF]

Pharmacotherapy
Antimicrobial resistance poses a significant public health challenge, particularly with the rise of gram‐negative hospital‐acquired infections resistant to carbapenems.
Al Musawa M, Bleick CR, Herbin SR, Caniff KE, Van Helden SR, Rybak MJ.   +5 more
europepmc   +4 more sources

Characterization of Metallo β-Lactamase Producing Enterobacterales Isolates with Susceptibility to the Aztreonam/Avibactam Combination. [PDF]

Antibiotics (Basel)
Background/Objectives: Metallo-β-lactamases (MBLs) in Enterobacterales and other Gram-negative organisms pose significant public health threats due to their association with multidrug resistance (MDR).
Posteraro B, De Maio F, Spanu T, Vidal Pereira MA, Fasano FR, Sanguinetti M.   +5 more
europepmc   +7 more sources

Whole-genome analysis of NDM-producing Providencia hangzhouensis associated with recurrent bacteraemia with rapid development of aztreonam-avibactam resistance [PDF]

Emerging Microbes and Infections
A 60-year-old male with recurrent bacteremia associated with necrotizing pancreatitis was followed over 17 months, during which six clinical isolates of Providencia were obtained. The index isolate (R1) was susceptible to aztreonam-avibactam (MIC 4 mg/L),
Ka Lip Chew, Yuan Qiao, Priscillia Lye, Joey Cruz Cabang, Nur Aisyah Binte Abu Bakar, Ker Xin Tan, Jeanette Teo   +6 more
doaj   +3 more sources

P-1256. Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analyses for Aztreonam-Avibactam Dosing Regimens [PDF]

Open Forum Infect Dis
Background Aztreonam-avibactam (ATM-AVI) is a fixed-ratio β-lactam/β-lactamase inhibitor recently approved in Europe for adults with serious Gram-negative infections. Prior to commercial availability of ATM-AVI, doses for ceftazidime-avibactam (CAZ-AVI) +
Susan R. Raber, Rujia Xie, Elena Soto, H. Leister-Tebbe   +3 more
europepmc   +3 more sources

In Vitro Activity of Cefiderocol and Aztreonam/Avibactam Against Gram-Negative Non-Fermenting Bacteria: A New Strategy Against Highly Antibiotic-Resistant Infectious Agents [PDF]

Antibiotics
Background/Objectives: Non-fermenting Gram-negative bacilli (NFGNB) represent a significant clinical challenge due to their intrinsic and acquired resistance, particularly in immunocompromised patients.
Jan Závora, Václava Adámková, Alžběta Studená, Gabriela Kroneislová   +3 more
doaj   +3 more sources

Aztreonam-avibactam synergy, a validation and comparison of diagnostic tools. [PDF]

Front Microbiol, 2023
IntroductionAntimicrobial resistance is a growing problem that necessitates the development of new therapeutic options. Cefiderocol and aztreonam (AT) are often the last active β-lactams for treating metallo-β-lactamases (MBL)-producing Gram-negative bacilli.
Verschelden G, Noeparast M, Stoefs A, Van Honacker E, Vandoorslaer K, Vandervore L, Olbrecht M, Van Damme K, Demuyser T, Piérard D, Wybo I.   +10 more
europepmc   +8 more sources

Resistance to aztreonam-avibactam due to a mutation of SHV-12 in Enterobacter

Annals of Clinical Microbiology and Antimicrobials, 2023
Aztreonam-avibactam is an important option against Enterobacterales producing metallo-β-lactamases (MBLs). We obtained an aztreonam-avibactam-resistant mutant of an MBL-producing Enterobacter mori strain by induced mutagenesis. Genome sequencing revealed
Shikai Wu, Ke Ma, Yu Feng, Zhiyong Zong
doaj   +3 more sources

Rapid Aztreonam/Avibactam NP test for detection of aztreonam/avibactam susceptibility/resistance in Enterobacterales. [PDF]

J Clin Microbiol, 2023
ABSTRACT Aztreonam-avibactam (AZA), a newly developed β-lactam/β-lactamase inhibitor combination , is a treatment option for infections due to carbapenem-resistant Enterobacterales (CRE), including metallo-ß-lactamase producers, regardless of additional production of broad-spectrum serine-ß-lactamases ...
Viguier C, Bouvier M, Sadek M, Kerbol A, Poirel L, Nordmann P.   +5 more
europepmc   +3 more sources